PA
STE icon

PharVision Advisers’s Steris STE Stock Holding History

PharVision Advisers’s Portfolio STE Stock Details STE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-881
Closed -$223K – 574
2025
Q4 		$223K Buy
+881
New +$221K 0.11% 465
2025
Q3 		– Sell
-1,283
Closed -$308K – 789
2025
Q2 		$308K Buy
+1,283
New +$299K 0.44% 76

Other funds holding STE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

PharVision Advisers's STE Position: Q1 2026 in Review

PharVision Advisers sold out of Steris (STE) in Q1 2026, closing a stake of 881 shares — an estimated $223K sold.

PharVision Advisers first reported a position in STE in Q2 2025 and held it in 2 quarters. The position peaked at $308K in Q2 2025. 838 funds tracked by Wall St. Rank hold STE as of Q1 2026.

  • PharVision Advisers reported no remaining Steris position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 881 Steris shares in Q1 2026, an estimated $223K.
  • PharVision Advisers first reported a position in Steris in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Steris position peaked at $308K in Q2 2025.
  • 838 funds tracked by Wall St. Rank held Steris as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.